Retrospective analysis data represents that breast cancer-bearing diabetic patients taking metformin had significant OS benefit either with or without DPP-4 inhibitors, whereas DPP-4 inhibitors alone displayed a worse trend [128]. This evidence concerns the gene DPP4 and breast cancer.